Kilitch Drugs (India) Balance Sheet Health
Financial Health criteria checks 5/6
Kilitch Drugs (India) has a total shareholder equity of ₹1.9B and total debt of ₹324.1M, which brings its debt-to-equity ratio to 17.2%. Its total assets and total liabilities are ₹2.6B and ₹709.5M respectively. Kilitch Drugs (India)'s EBIT is ₹154.0M making its interest coverage ratio 3.4. It has cash and short-term investments of ₹588.5M.
Key information
17.2%
Debt to equity ratio
₹324.12m
Debt
| Interest coverage ratio | 3.4x |
| Cash | ₹588.52m |
| Equity | ₹1.88b |
| Total liabilities | ₹709.50m |
| Total assets | ₹2.59b |
Recent financial health updates
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Recent updates
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar
Jul 23Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16Financial Position Analysis
Short Term Liabilities: KILITCH's short term assets (₹1.5B) exceed its short term liabilities (₹707.8M).
Long Term Liabilities: KILITCH's short term assets (₹1.5B) exceed its long term liabilities (₹1.7M).
Debt to Equity History and Analysis
Debt Level: KILITCH has more cash than its total debt.
Reducing Debt: KILITCH's debt to equity ratio has increased from 10.9% to 17.2% over the past 5 years.
Debt Coverage: KILITCH's debt is well covered by operating cash flow (64.9%).
Interest Coverage: KILITCH's interest payments on its debt are well covered by EBIT (3.4x coverage).